New data for Roche’s OCREVUS reinforce significant benefit on slowing disease progression in relapsing and primary progressive multiple sclerosis
OCREVUS significantly slowed loss of brain tissue within T2 MRI lesions in primary progressive multiple sclerosis (PPMS) in post-hoc analysis of Phase III ORATORIO study